Develops inhaled insulin and diuretics for diabetes and heart failure.
Jun 2026Revenue $394M/yrExpenses $384M/yr
No trend
Figures by year
Is Mannkind profitable?
Yes. In the 12 months to Jun 2026, revenue was $394M and expenses $384M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $349M | $310M | $38.8M |
| Dec 2024 | $286M | $213M | $72.6M |
| Dec 2023 | $199M | $190M | $8.68M |
| Dec 2022 | $99.8M | $164M | −$64.1M |
| Dec 2021 | $75.4M | $122M | −$47.0M |
| Dec 2020 | $65.1M | $113M | −$47.9M |
| Dec 2019 | $63.0M | $108M | −$44.6M |
| Dec 2018 | $27.9M | $104M | −$76.6M |
| Dec 2017 | $11.7M | $120M | −$108M |
| Dec 2016 | $175M | $107M | $67.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.